Literature DB >> 19047090

Ascites specific inhibition of CD1d-mediated activation of natural killer T cells.

Tonya J Webb1, Robert L Giuntoli, Ophelia Rogers, Jonathan Schneck, Mathias Oelke.   

Abstract

PURPOSE: Natural killer T (NKT) cells recognize lipid antigen presented by CD1 molecules. NKT cells can both directly, through cytotoxicity, and indirectly, through activation of other effector cells, mediate antitumor immunity. It has been shown, however, that tumor-associated lipids are frequently shed into the tumor microenvironment, which can mediate immunosuppressive activity. Given that ovarian cancer-associated ascites has been reported to have increased levels of gangliosides, we examined the effect of tumor-associated and other ascites on CD1d-mediated antigen presentation to NKT cells. EXPERIMENTAL
DESIGN: To investigate the effects of ascites on NKT cell activation, we pretreated CD1d-expressing cells with the ascites and measured their ability to stimulate cytokine production in NKT cells. To determine whether antigen processing or editing was necessary, CD1d-immunoglobulin-based artificial antigen presenting cells (aAPC) were also incubated with ascites. In addition, to examine specificity, we analyzed whether ascites fluid could influence the activation of classic CD8+ T cells.
RESULTS: Pretreatment of CD1d-expressing cells with ascites from the majority of patients inhibited the ability of the cells to stimulate/activate NKT cells in a dose-dependent manner. Ascites treatment also partially blocked the ability of alpha-galactosylceramide-loaded CD1d-immunoglobulin-based aAPC to activate NKT cells. In addition, our data show that treatment with ascites does not inhibit HLA-A2-mediated activation of classic CD8+ T cells.
CONCLUSIONS: Together, these data suggest that ovarian and other cancers may have developed immune evasion mechanisms specifically targeting the CD1/NKT cell system.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19047090      PMCID: PMC2676584          DOI: 10.1158/1078-0432.CCR-08-1468

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  35 in total

1.  Multiple defects in antigen presentation and T cell development by mice expressing cytoplasmic tail-truncated CD1d.

Authors:  Ya-Hui Chiu; Se-Ho Park; Kamel Benlagha; Claire Forestier; Jayanthi Jayawardena-Wolf; Paul B Savage; Luc Teyton; Albert Bendelac
Journal:  Nat Immunol       Date:  2001-12-03       Impact factor: 25.606

2.  Granulocyte-macrophage colony-stimulating factor regulates effector differentiation of invariant natural killer T cells during thymic ontogeny.

Authors:  Jelena S Bezbradica; Laura E Gordy; Aleksandar K Stanic; Srdjan Dragovic; Timothy Hill; Jacek Hawiger; Derya Unutmaz; Luc Van Kaer; Sebastian Joyce
Journal:  Immunity       Date:  2006-08-31       Impact factor: 31.745

Review 3.  Application of natural killer T cells in antitumor immunotherapy.

Authors:  Changwan Hong; Se-Ho Park
Journal:  Crit Rev Immunol       Date:  2007       Impact factor: 2.214

Review 4.  Activation of natural killer T cells by glycolipids.

Authors:  Emmanuel Tupin; Mitchell Kronenberg
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

5.  Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells.

Authors:  A D Santin; S Bellone; A Ravaggi; S Pecorelli; M J Cannon; G P Parham
Journal:  Obstet Gynecol       Date:  2000-09       Impact factor: 7.661

6.  Reduced cell migration, tumor growth and experimental metastasis of rat F-11 cells whose expression of GD3-synthase is suppressed.

Authors:  G Zeng; L Gao; R K Yu
Journal:  Int J Cancer       Date:  2000-10-01       Impact factor: 7.396

7.  Recycling CD1d1 molecules present endogenous antigens processed in an endocytic compartment to NKT cells.

Authors:  Tonya J Roberts; Venkataraman Sriram; Philip M Spence; Ming Gui; Kyoko Hayakawa; Igor Bacik; Jack R Bennink; Jonathan W Yewdell; Randy R Brutkiewicz
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

8.  Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand.

Authors:  Jun-Eui Park; Dianna Y Wu; Maria Prendes; Sharon X Lu; Govind Ragupathi; Nicolas Schrantz; Paul B Chapman
Journal:  Immunology       Date:  2008-01       Impact factor: 7.397

Review 9.  Immunotherapy opportunities in ovarian cancer.

Authors:  Christina S Chu; Sarah H Kim; Carl H June; George Coukos
Journal:  Expert Rev Anticancer Ther       Date:  2008-02       Impact factor: 4.512

10.  Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells.

Authors:  Christian Schütz; Martin Fleck; Andreas Mackensen; Alessia Zoso; Dagmar Halbritter; Jonathan P Schneck; Mathias Oelke
Journal:  Blood       Date:  2007-12-20       Impact factor: 22.113

View more
  14 in total

1.  Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer.

Authors:  Tonya J Webb; Xiangming Li; Robert L Giuntoli; Pablo H H Lopez; Christoph Heuser; Ronald L Schnaar; Moriya Tsuji; Christian Kurts; Mathias Oelke; Jonathan P Schneck
Journal:  Cancer Res       Date:  2012-05-30       Impact factor: 12.701

2.  Oxidative dna damage of lymphocytes in peripheral blood and ascites in cancer patients.

Authors:  J Wang; S S Xing; S B Guo; W Jin; W Zhang
Journal:  Curr Oncol       Date:  2012-07       Impact factor: 3.677

3.  Invariant natural killer T cells generated from human adult hematopoietic stem-progenitor cells are poly-functional.

Authors:  Wenji Sun; Yi Wang; James E East; Amy S Kimball; Katherine Tkaczuk; Susan Kesmodel; Scott E Strome; Tonya J Webb
Journal:  Cytokine       Date:  2015-01-05       Impact factor: 3.861

4.  CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer.

Authors:  Elda Righi; Satoshi Kashiwagi; Jianping Yuan; Michael Santosuosso; Pierre Leblanc; Rachel Ingraham; Benjamin Forbes; Beth Edelblute; Brian Collette; Deyin Xing; Magdalena Kowalski; Maria Cristina Mingari; Fabrizio Vianello; Michael Birrer; Sandra Orsulic; Glenn Dranoff; Mark C Poznansky
Journal:  Cancer Res       Date:  2011-07-08       Impact factor: 12.701

5.  Dietary fatty acids modulate antigen presentation to hepatic NKT cells in nonalcoholic fatty liver disease.

Authors:  Jing Hua; Xiong Ma; Tonya Webb; James J Potter; Mathias Oelke; Zhiping Li
Journal:  J Lipid Res       Date:  2010-02-24       Impact factor: 5.922

6.  The detection, treatment, and biology of epithelial ovarian cancer.

Authors:  Jennifer Aa Gubbels; Nick Claussen; Arvinder K Kapur; Joseph P Connor; Manish S Patankar
Journal:  J Ovarian Res       Date:  2010-03-29       Impact factor: 4.234

7.  Human CD1 dimeric proteins as indispensable tools for research on CD1-binding lipids and CD1-restricted T cells.

Authors:  Takayuki Shiratsuchi; Jonathan Schneck; Akira Kawamura; Moriya Tsuji
Journal:  J Immunol Methods       Date:  2009-04-15       Impact factor: 2.303

8.  Natural killer T cell based Immunotherapy.

Authors:  Priyanka B Subrahmanyam; Wenji Sun; James E East; Junxin Li; Tonya J Webb
Journal:  J Vaccines Vaccin       Date:  2012-08-23

9.  VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells.

Authors:  Irina V Tiper; Sarah M Temkin; Sarah Spiegel; Simeon E Goldblum; Robert L Giuntoli; Mathias Oelke; Jonathan P Schneck; Tonya J Webb
Journal:  Clin Cancer Res       Date:  2016-04-13       Impact factor: 12.531

Review 10.  Targeting Natural Killer T Cells in Solid Malignancies.

Authors:  Zewde Ingram; Shriya Madan; Jenoy Merchant; Zakiya Carter; Zen Gordon; Gregory Carey; Tonya J Webb
Journal:  Cells       Date:  2021-05-27       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.